It’s been a crucial week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ); here’s what analysts have to say.

March 21, 2018 - By Marguerite Chambers

 It's been a crucial week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ); here's what analysts have to say.
Investors sentiment decreased to 1.03 in Q3 2017. Its down 0.36, from 1.39 in 2017Q2. It worsened, as 39 investors sold Jazz Pharmaceuticals plc shares while 82 reduced holdings. 31 funds opened positions while 94 raised stakes. 53.58 million shares or 3.54% more from 51.74 million shares in 2017Q2 were reported.
Glenmede Tru Na stated it has 13 shares or 0% of all its holdings. Reilly Fincl Advisors Ltd Limited Liability Company has 23 shares for 0% of their portfolio. Schroder Inv Mngmt Grp Inc holds 354,900 shares. Whittier Tru has 10 shares for 0% of their portfolio. Vident Inv Advisory Limited Com has invested 0.18% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Sg Americas Securities Ltd Liability owns 1,383 shares for 0% of their portfolio. Gratry And Communications Limited Liability Co reported 2.42% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Raymond James Assoc holds 0.01% or 22,918 shares in its portfolio. Fincl Bank Of Montreal Can reported 55,404 shares or 0.01% of all its holdings. Strs Ohio, Ohio-based fund reported 250,800 shares. Endurant Management Ltd Partnership invested 0.82% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Shaker Ltd Oh holds 0.59% or 5,789 shares. Morgan Stanley holds 0.01% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 242,720 shares. Columbus Circle Investors holds 58,512 shares. Raymond James Finance Serv holds 2,607 shares.

Since October 2, 2017, it had 0 insider buys, and 13 selling transactions for $3.06 million activity. The insider Treacy Paul sold 594 shares worth $84,030. 3,135 shares valued at $460,381 were sold by Young Matthew P. on Monday, February 26. $150,000 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was sold by COZADD BRUCE C. $1.26M worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was sold by ENRIGHT PATRICK G.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 22 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 18 have Buy rating, 0 Sell and 4 Hold. Therefore 82% are positive. Jazz Pharmaceuticals had 77 analyst reports since August 3, 2015 according to SRatingsIntel. The company was upgraded on Monday, April 25 by SunTrust. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Hold” rating given on Thursday, October 5 by Morgan Stanley. FBR Capital initiated the stock with “Buy” rating in Wednesday, October 18 report. The firm has “Buy” rating by SunTrust given on Friday, November 3. The firm earned “Buy” rating on Friday, July 14 by Piper Jaffray. On Tuesday, September 19 the stock rating was maintained by BMO Capital Markets with “Buy”. The company was maintained on Tuesday, June 27 by Cantor Fitzgerald. The firm has “Buy” rating by Bank of America given on Tuesday, February 20. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Wednesday, June 7 by BMO Capital Markets. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Overweight” rating by Morgan Stanley on Monday, March 19. Below is a list of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) latest ratings and price target changes.

19/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade
16/03/2018 Broker: Leerink Swann Rating: Buy New Target: $180.0 Maintain
09/03/2018 Broker: FBR Capital Rating: Buy New Target: $206.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $202.0 Maintain
28/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $196 New Target: $199 Maintain
20/02/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $164 New Target: $170 Maintain
30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $194.0 Maintain
11/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $196.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $180.0 Maintain
02/01/2018 Broker: Leerink Swann Rating: Buy New Target: $180.0 Initiate

The stock decreased 1.85% or $2.9 during the last trading session, reaching $154.26. About 360,321 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has risen 1.25% since March 21, 2017 and is uptrending. It has underperformed by 15.45% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $9.23 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 19.38 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: